未来治疗乙型肝炎病毒：免疫调节剂的作用 作者 作者

StephenW

Future Therapy for Hepatitis B Virus: Role of Immunomodulators

• Authors
• Authors and affiliations
  
  

• Edward A. Pham
• Ryan B. Perumpail
• Benjamin J. Fram
• Jeffrey S. Glenn
• Aijaz Ahmed
• Robert G. GishEmail author
  

• Edward A. Pham
  
  • 1
  • 2
    
• Ryan B. Perumpail
  
  • 1
    
• Benjamin J. Fram
  
  • 1
    
• Jeffrey S. Glenn
  
  • 1
  • 2
  • 3
    
• Aijaz Ahmed
  
  • 1
    
• Robert G. Gish
  
  • 1
  • 4
    
  Email author

• 1.Department of Medicine, Division of Gastroenterology and HepatologyStanford University School of MedicineStanfordUSA
• 2.Department of Microbiology and ImmunologyStanford University School of MedicineStanfordUSA
• 3.Veterans Administration Medical CenterPalo AltoUSA
• 4.Hepatitis B FoundationDoylestownUSA
  

Open AccessHepatitis B (JK Lim, Section Editor)First Online: 10 November 2016

DOI:            10.1007/s11901-016-0315-9

Cite this article as: Pham, E.A., Perumpail, R.B., Fram, B.J. et al. Curr Hepatology Rep (2016) 15: 237. doi:10.1007/s11901-016-0315-9   

•                      108                     Downloads
  

Part of the following topical collections:

• Topical Collection on Hepatitis B
  

Abstract

Although currently available therapies for chronic hepatitis B virus infection can suppress viremia and provide long-term benefits for patients, they do not lead to a functional cure for most patients. Advances in our understanding of the virus-host interaction and the recent remarkable success of immunotherapy in cancer offer new and promising strategies for developing immune modulators that may become important components of a total therapeutic approach to hepatitis B, some of which are now in clinical development. Among the immunomodulatory agents currently being investigated to combat chronic HBV are toll-like receptor agonists, immune checkpoint inhibitors, therapeutic vaccines, and engineered T cells. The efficacy of some immune modulatory therapies is compromised by high viral antigen levels. Cutting edge strategies, including RNA interference and CRISPR/Cas9, are now being studied that may ultimately be shown to have the capacity to lower viral antigen levels sufficiently to substantially increase the efficacy of these agents. The current advances in therapies for chronic hepatitis B are leading us toward the possibility of a functional cure.

KeywordsHepatitis BImmune modulatorsToll-like receptor agonistsCheckpoint inhibitorsTherapeutic vaccinesEngineered T cellsRNA interferenceCRISPR/Cas9

This article is part of the Topical Collection on Hepatitis B

StephenW

未来治疗乙型肝炎病毒：免疫调节剂的作用

    作者
    作者和关系

    Edward A. PhamRyan B. Perumpail Benjamin J. FramJeffrey S. GlennAijaz AhmedRobert G. GishEmail author

    爱德华A.
        12
    Ryan B. Perumpail
        1
    Benjamin J. Fram
        1
    Jeffrey S. Glenn
        123
    Aijaz艾哈迈德
        1
    罗伯特·Gish
        14电子作者

    1.医学部，消化内科和肝病科斯坦福大学医学院Stanford美国
    微生物学和免疫学部斯坦福大学医学院StanfordUSA
    退伍军人管理医疗中心
    乙型肝炎基金会

开放性乙型肝炎（JK Lim，Section Editor）

首先在线：
    2016年11月10日

DOI：10.1007 / s11901-016-0315-9

引用本文：
    Pham，E.A.，Perumpail，R.B.，Fram，B.J.et al。 Curr Hepatology Rep（2016）15：237。doi：10.1007 / s11901-016-0315-9

    108下载

以下主题集合的一部分：

    关于乙型肝炎的专题收集

抽象

虽然目前可用的慢性乙型肝炎病毒感染的治疗可以抑制病毒血症并为患者提供长期益处，但它们不能导致大多数患者的功能性治愈。我们对病毒 - 宿主相互作用的理解的进展以及免疫治疗在癌症中最近的显着成功提供了用于开发可能成为乙型肝炎的总治疗方法的重要组成部分的免疫调节剂的新的和有希望的策略，其中一些已经在临床开发中。目前正研究对抗慢性HBV的免疫调节剂是toll样受体激动剂，免疫检查点抑制剂，治疗性疫苗和工程改造的T细胞。一些免疫调节治疗的功效受到高病毒抗原水平的影响。目前正在研究包括RNA干扰和CRISPR / Cas9的切缘策略，其最终可以显示具有足以降低病毒抗原水平以显着增加这些试剂的功效的能力。目前在慢性乙型肝炎治疗方面的进展正在引领我们走向功能性治愈的可能性。
关键词
肝炎BImmune调节剂类似受体激动剂检查点抑制剂治疗疫苗工程化T细胞RNA干扰CRISPR / Cas9

本文是乙型肝炎专题收集的一部分

StephenW

http://link.springer.com/article ... =alerts.TOCjournals